Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Therapeutics

• Publication date

  2013-04-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.clinthera.2013.03.001PMID 23587268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucocorticoid use and abuse in SLE.

  2012cited by this paper
• Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.

  2011cited by this paper
• Systemic lupus erythematosus.

  2010cited by this paper
• New directions in the treatment of systemic lupus erythematosus

  2009cited by this paper
• The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

  2009cited by this paper
• Mechanisms of Disease Systemic Lupus Erythematosus

  2008cited by this paper
• Adverse Drug Events in U.S. Hospitals, 2004

  2007cited by this paper
• Medication therapy in ambulatory medical care: United States, 2003-04.

  2006cited by this paper
• The cost of glucocorticoid-associated adverse events in rheumatoid arthritis.

  2005cited by this paper
• Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review.

  2005cited by this paper
• Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action.

  2004cited by this paper
• Damage in systemic lupus erythematosus and its association with corticosteroids.

  2000cited by this paper
• Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.

  1999cited by this paper
• Practical considerations on the use of the Charlson comorbidity index with administrative data bases.

  1996cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

  1993cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper

• Disease Severity and Healthcare Costs Associated With Chronic Kidney Disease in Patients With Systemic Lupus Erythematosus.

  2026cites this paper
• Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database

  2025cites this paper
• Efficacy and safety of belimumab in lupus nephritis patients with nephrotic syndrome: a single-centre observational retrospective study

  2025cites this paper
• Endocrine and metabolic comorbidities in juvenile-onset systemic lupus erythematosus

  2025cites this paper
• Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action.

  2024cites this paper
• Modelling long-term outcomes for patients with systemic lupus erythematosus.

  2024cites this paper
• Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study

  2024cites this paper
• Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement

  2024influential citation
• Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis

  2024influential citation
• Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States.

  2023cites this paper
• Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK

  2023influential citation
• Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus.

  2023cites this paper
• Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study

  2023cites this paper
• Design of Multitarget Inhibitors as Tracheal Smooth Muscle Relaxants.

  2023cites this paper
• Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden

  2023cites this paper
• Effectiveness of transcranial direct current stimulation (tDCS) as adjunctive treatment for chronic headache in adults with clinically stable systemic lupus erythematosus (SHADE): a randomised double-blind multiarm sham controlled clinical trial

  2023cites this paper
• Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis

  2023cites this paper
• Chronic corticosteroid use is associated with substantial clinical and economic burden in patients with Crohn's Disease initiated on biologic or conventional therapies in the US: A retrospective study.

  2023cites this paper
• Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis

  2023cites this paper
• A network-based drug repurposing approach identifies new treatment opportunities for the systemic chronic inflammation underlying multiple complex diseases

  2022cites this paper
• Asthma burden according to treatment steps in the French population-based cohort CONSTANCES.

  2022cites this paper
• A network-based approach for isolating the chronic inflammation gene signatures underlying complex diseases towards finding new treatment opportunities

  2022cites this paper
• Factors Related to Infection in Systemic Lupus Erythematosus Patients Admitted to the Hospital

  2022cites this paper
• Short- and long-term oral steroid therapy in patients with asthma exacerbation.

  2022cites this paper
• Health care utilization and costs of systemic lupus erythematosus in the United States: A systematic review

  2022cites this paper
• Herpes zoster in SLE: prevalence, incidence and risk factors

  2022cites this paper
• Awareness of Oral Corticosteroid Use among Sudanese with Rheumatological Diseases: A Single Centre Study

  2021cites this paper
• Corticosteroid Use and Risk of Herpes Zoster in a Population-Based Cohort.

  2021cites this paper
• Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015

  2021cites this paper
• Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015

  2021cites this paper
• Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper

  2020cites this paper
• Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study.

  2020cites this paper
• Risk factors for cataracts in a cohort of Egyptian systemic lupus erythematosus patients

  2020cites this paper
• Defining Depression and Anxiety in Individuals With Rheumatic Diseases Using Administrative Health Databases: A Systematic Review

  2020cites this paper
• Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

  2020cites this paper
• Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

  2020cites this paper
• Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

  2020cites this paper
• A Review on Corticosteroids and Its Clinical Complications on Long Term Exposure

  2020cites this paper
• Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

  2020cites this paper
• Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population

  2020cites this paper
• Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

  2019cites this paper
• Recurrent Mycobacterium tuberculosis infection in systemic lupus erythematosus patient: case report and review

  2019cites this paper
• Adverse events related to low dose corticosteroids in autoimmune hepatitis

  2019cites this paper
• Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis

  2019cites this paper
• Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial

  2018influential citation
• Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long‐Term Disease Control: An Observational Study

  2018cites this paper
• Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population

  2018cites this paper
• Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus

  2018cites this paper
• A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma

  2018cites this paper
• Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population

  2018cites this paper
• Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study

  2018cites this paper
• Oral corticosteroid exposure and adverse effects in asthmatic patients

  2018cites this paper
• Burden of systemic glucocorticoid-related complications in severe asthma

  2017cites this paper
• Depression in Patients with Systemic Lupus Erythematosus: A Multicenter Study

  2017cites this paper
• Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

  2017cites this paper
• Health-related quality of life associated with systemic corticosteroids

  2017cites this paper
• Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review.

  2017cites this paper
• Infections and systemic lupus erythematosus Infecções e lúpus eritematoso sistêmico

  2016cites this paper
• Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

  2016cites this paper
• Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

  2016cites this paper
• Infections and systemic lupus erythematosus

  2016cites this paper
• Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis

  2016cites this paper
• Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study

  2016cites this paper
• Herpes zoster in the immunocompromised..... 1 Risk of Herpes Zoster in Individuals on Biologics, DMARDS and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta- Analysis

  2016cites this paper
• Morbidity associated with oral corticosteroids in patients with severe asthma

  2016cites this paper
• Physicians Perception towards Corticosteroids as Therapeutic Agent: A Survey

  2015cites this paper
• Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study

  2015cites this paper
• Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs

  2015cites this paper
• Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011

  2015cites this paper
• Risk factors for cataracts in systemic lupus erythematosus (SLE)

  2015cites this paper
• Enhanced Steroid Therapy in Adult Minimal Change Nephrotic Syndrome: A Systematic Review and Meta-analysis.

  2015cites this paper
• Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel

  2014influential citation
• Predictors of Incident Depression in Systemic Lupus Erythematosus

  2014cites this paper
• Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?

  2013cites this paper